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Analysis of cell-free circulating tumor DNA (cfDNA) isolated from patient plasma offers an attractive alternative to serial tumor biopsies for monitoring disease progression 
in non–small-cell lung cancer (NSCLC). Convenient and minimally invasive, analysis of 
cfDNA from blood has the potential to transform cancer treatment if certain thresholds 
for validation (sensitivity, specificity, and reproducibility) can be met. In theory, tumor-
specific genetic changes that confer resistance to a previously successful treatment regimen 
could be identified in a timely fashion using this approach. Serial monitoring of tumor 
status enabled by periodic blood draws would grant physicians an opportunity to address 
and perhaps even counter resistance mechanisms early in their emergence, before full-
blown clinical progression. In many ways, NSCLC is the ideal disease in which to test such 
approaches: coupled to the advent of highly active therapies targeting epidermal growth 
factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) is a plethora of acquired 
resistance mechanisms that provide avenues of escape for the tumor. These include, but 
certainly are not limited to, the EGFR T790M mutation that interferes with the affinity 
of first-generation EGFR tyrosine kinase inhibitor, various acquired ALK mutations that 
render ALK-fusions refractory to crizotinib-mediated inhibition, and bypass signaling from 
newly activated oncogenes such as MET, HER2, or AXL. Suitable therapeutic strategies 
already exist to combat many of the resistance mechanisms common to EGFR and ALK-
based regimens, yet it remains to be determined whether early detection and intervention 
can improve patient overall survival.
In this issue of JTO, Jeng-Sen Tseng et al. demonstrate progress toward this goal by 
examining the significance of plasma mutation positivity (defined here as the detection of 
EGFR mutant alleles in cfDNA) over time in a set of patients with known tumor EGFR 
mutation status. Focusing on patients where EGFR mutations were detectable in cfDNA at 
baseline, the authors analyzed mutant allele frequencies in plasma at 10 weeks into EGFR 
tyrosine kinase inhibitor therapy. The subset of patients with persistent plasma positiv-
ity at this time point fared significantly worse than those where EGFR mutant alleles 
fell below the level of detection. Specifically, failure to “clear” plasma was associated 
with significantly worse response rates, disease control rates, progression-free survival, 
and most notably overall survival, where patients with persistent cfDNA positivity had 
a median overall survival of 10.8 months versus those with plasma clearance achieving 
a median of 20.5 months (p = 0.012). In this study, not all patients with EGFR-mutant 
tumor-positivity had plasma-positivity. Of 62 patients with mutant-positive tumors, only 
37 patients had corresponding detectable mutations in plasma, for an overall sensitiv-
ity of 60%. However, it should be pointed out that plasma positivity was significantly 
more prevalent in patients classified as stage IV-M1b (78%) versus those with stage IIIA 
or IV-M1a (23%), consistent with the supposition that increased tumor-specific DNA in 
peripheral circulation is an indicator of a more aggressive disease. At this point in their 
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research, the authors did not analyze blood draws acquired 
at tumor progression or look for the emergence (or de novo 
presence) of the T790M resistance mutation. Nevertheless, 
this report adds further evidence to support the viability of 
plasma-based tumor genetic monitoring.
Ultimately, for clinical implementation and routine ther-
apeutic decision-making, assays based on blood-borne tumor 
DNA in peripheral circulation will need to meet the strin-
gent requirements for an FDA-approved diagnostic test. The 
growing list of high sensitivity, high specificity techniques for 
mutation detection strongly suggest that this criterion will be 
met. At both academic and commercial labs, assay sensitivi-
ties of less than 0.1% (i.e., the detection of one mutant allele 
in a pool of 1000 wild-type alleles) are now being reported, 
with 100% specificity (i.e., no false positives). Ongoing 
efforts to achieve and commercialize this level of perfor-
mance for cfDNA applications beyond single-mutation assays 
will greatly enhance the utility of this approach for identify-
ing emergent resistance mechanisms or tumor recurrence. In 
development are platforms for conducting error-proof next-
generation sequencing, and techniques for assessing relative 
RNA expression levels and tumor DNA copy number abnor-
malities in plasma samples.
Although metastatic NSCLC remains essentially incur-
able, advances in cfDNA analysis that provide actionable 
insight into tumor dynamics are an immeasurable step for-
ward in achieving the goal of long-term disease control for 
tumors with identifiable, targetable driver mutations. If there 
is one thing cancer patients have become accustomed to, it is 
the insatiable need on the part of physician and researchers to 
draw their blood. Finally, however, with the convergence of 
incredibly sensitive technology and an improved understand-
ing of fundamental tumor biology, all that blood may be worth 
the sweat and tears.
